Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia December 13, 2024 — 07:52 pm EST Written by RTTNews.com for RTTNews -> ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including ...

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to ...

Neurocrine Biosciences announced that its experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial of children and adolescents.

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) said that it will no longer be pursuing development of BBP-631 for Congenital Adrenal Hyperplasia. The company is actively seeking partnership ...

Featuring articles on crinecerfont in pediatric and adult congenital adrenal hyperplasia, the postacute sequelae of SARS-CoV-2 infection, and nipocalimab in early-onset severe hemolytic disease of ...

Dec. 17, 2024 – The FDA has approved crinecerfont, a first-in-class oral drug for treating classic congenital adrenal hyperplasia (CAH), a rare genetic condition present from birth. It is ...